Aerpio Pharmaceuticals Inc (ARPO) Stock Price, Quote, News and Overview
NASDAQ:ARPO - Nasdaq -
ARPO Quote, Performance and Key Statistics
2.2
-0.02 (-0.9%)
The current stock price of ARPO is 2.2 null. In the past month the price increased by 3.77%. In the past year, price increased by 65.41%.
ARPO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About ARPO
Company Profile
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Loveland, Ohio and currently employs 12 full-time employees. The company went IPO on 2018-06-26. The firm is focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Its lead product candidate is razuprotafib. Razuprotafib, is a small molecule VE-PTP inhibitor, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. The firm is also developing a bispecific antibody that binds both VEGF and VE-PTP, which is designed to inhibit VEGF activation and activate Tie2. The firm's pipeline includes Razuprotafib (AKB-9778) Open Angle Glaucoma, Razuprotafib Acute Respiratory Distress Syndrome (ARDS)/ COVID-19, Razuprotafib Diabetic Kidney Disease, ARP-1536 Retinopathy/Nephropathy and Bispecific Ab Retinopathy/Cancer.
Company Info
Aerpio Pharmaceuticals Inc
10663 LOVELAND-MADEIRA ROAD #168
Loveland OHIO 45242 US
CEO: Joseph Gardner
Employees: 12
Company Website: https://aerpio.com/
Phone: 15139851920.0
Aerpio Pharmaceuticals Inc / ARPO FAQ
What is the stock price of Aerpio Pharmaceuticals Inc today?
The current stock price of ARPO is 2.2 null. The price decreased by -0.9% in the last trading session.
What is the ticker symbol for Aerpio Pharmaceuticals Inc stock?
The exchange symbol of Aerpio Pharmaceuticals Inc is ARPO and it is listed on the Nasdaq exchange.
On which exchange is ARPO stock listed?
ARPO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Aerpio Pharmaceuticals Inc stock?
2 analysts have analysed ARPO and the average price target is 47.94 null. This implies a price increase of 2079.09% is expected in the next year compared to the current price of 2.2. Check the Aerpio Pharmaceuticals Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Aerpio Pharmaceuticals Inc worth?
Aerpio Pharmaceuticals Inc (ARPO) has a market capitalization of 104.85M null. This makes ARPO a Micro Cap stock.
How many employees does Aerpio Pharmaceuticals Inc have?
Aerpio Pharmaceuticals Inc (ARPO) currently has 12 employees.
What are the support and resistance levels for Aerpio Pharmaceuticals Inc (ARPO) stock?
Aerpio Pharmaceuticals Inc (ARPO) has a support level at 2.04 and a resistance level at 2.31. Check the full technical report for a detailed analysis of ARPO support and resistance levels.
Is Aerpio Pharmaceuticals Inc (ARPO) expected to grow?
The Revenue of Aerpio Pharmaceuticals Inc (ARPO) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ARPO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Aerpio Pharmaceuticals Inc (ARPO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ARPO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ARPO, evaluating the profitability, health, valuation and growth aspects
- Aerpio Pharmaceuticals Inc (ARPO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Aerpio Pharmaceuticals Inc (ARPO) Sales and EPS estimates to see what analysts future expectations are.
- Aerpio Pharmaceuticals Inc (ARPO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Aerpio Pharmaceuticals Inc (ARPO) Insider and Institutional Ownership to learn about the owners and their transactions.
- Aerpio Pharmaceuticals Inc (ARPO) Stock Chart to make your own analysis
- Aerpio Pharmaceuticals Inc (ARPO) Latest news and press-releases to stay up to date.
Does Aerpio Pharmaceuticals Inc (ARPO) stock pay dividends?
ARPO does not pay a dividend.
What is the Price/Earnings (PE) ratio of Aerpio Pharmaceuticals Inc (ARPO)?
Aerpio Pharmaceuticals Inc (ARPO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).
ARPO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ARPO. When comparing the yearly performance of all stocks, ARPO is one of the better performing stocks in the market, outperforming 85.4% of all stocks.
ARPO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARPO. While ARPO has a great health rating, there are worries on its profitability.
ARPO Financial Highlights
Over the last trailing twelve months ARPO reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS decreased by -355.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.49% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ARPO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 100% to ARPO. The Buy consensus is the average rating of analysts ratings from 2 analysts.
For the next year, analysts expect an EPS growth of 33.81% and a revenue growth -100% for ARPO